US2013045916A1PendingUtilityA1

Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof

50
Assignee: REGEANTS OF THE UNIVERSITY OF CALIFORNIAPriority: May 30, 2007Filed: Oct 9, 2012Published: Feb 21, 2013
Est. expiryMay 30, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Nir BarzilaiPinchas CohenRadhika MuzumdarDavid J. Lefer
C07K 14/47A61K 38/1709A61P 3/10C07K 14/4711A61K 38/1716
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.

Claims

exact text as granted — not AI-modified
1 - 91 . (canceled) 
     
     
         92 . A pharmaceutical composition for increasing insulin sensitivity comprising humanin or a humanin analog in an amount effective to increase insulin sensitivity and a pharmaceutically acceptable carrier, wherein humanin or the humanin analog comprises the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:19. 
     
     
         93 . The pharmaceutical composition of  claim 92 , wherein humanin has the amino acid sequence of SEQ ID NO:1. 
     
     
         94 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:2. 
     
     
         95 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:3. 
     
     
         96 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:4. 
     
     
         97 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:5. 
     
     
         98 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:6. 
     
     
         99 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:7. 
     
     
         100 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:8. 
     
     
         101 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:9. 
     
     
         102 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:11. 
     
     
         103 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:19. 
     
     
         104 . The pharmaceutical composition of  claim 92 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:10 conjugated to the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:19. 
     
     
         105 . The pharmaceutical composition of  claim 104 , wherein the humanin analog comprises the amino acid sequence of SEQ ID NO:10 at the N-terminus of the amino acid sequence of amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11 or SEQ ID NO:19. 
     
     
         106 . A method of increasing insulin sensitivity in a subject exhibiting insulin resistance comprising administering the pharmaceutical composition of  claim 92  to the subject. 
     
     
         107 . A method of treating type-2 diabetes mellitus in a subject comprising administering the pharmaceutical composition of  claim 92  to the subject.

Join the waitlist — get patent alerts

Track US2013045916A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.